(Q40299060)

19 September 2017

title

A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome (English)

1 reference

hemorrhagic fever with renal syndrome

19 September 2017

main subject

phase I clinical trial

0 references

0 references

1 reference

Jay W Hooper

11

0 references

Connie S Schmaljohn

10

object named as

Connie Schmaljohn

1 reference

19 September 2017

2

Matthew Josleyn

1 reference

19 September 2017

Ellen F Boudreau

1

1 reference

19 September 2017

Diane Ullman

3

1 reference

19 September 2017

Diana Fisher

4

1 reference

19 September 2017

Lonnie Dalrymple

5

1 reference

19 September 2017

Karen Sellers-Myers

6

1 reference

19 September 2017

Peter Loudon

7

1 reference

19 September 2017

Janice Rusnak

8

1 reference

19 September 2017

Robert Rivard

9

1 reference

19 September 2017

language of work or name

English

0 references

publication date

14 January 2012

1 reference

19 September 2017

1 reference

19 September 2017

volume

30

1 reference

19 September 2017

issue

11

1 reference

19 September 2017

page(s)

1951-1958

1 reference

Vaccines against hantaviruses

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Recent approaches in hantavirus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Spatiotemporal trends and climatic factors of hemorrhagic fever with renal syndrome epidemic in Shandong Province, China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Hantavirus infections in humans and animals, China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Development and application of a flow cytometric potency assay for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Cross-Neutralization of Hantaviruses with Immune Sera from Experimentally Infected Animals and from Hemorrhagic Fever with Renal Syndrome and Hantavirus Pulmonary Syndrome Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Serological relationships among viruses in the Hantavirus genus, family Bunyaviridae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Antigenic relationship between hantaviruses analysed by immunoprecipitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

inferred from DOI database lookup

7 January 2021

based on heuristic

Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.024

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.01.024

1 reference

19 September 2017

1 reference